Petlife Pharmaceuticals, Inc. engages in the research, development, sale, and support of drugs and nutraceuticals for pet cancer and autoimmune related diseases, such as arthritis in the United States. The company's principal product is Vitalzul that inhibits blood vessels formation in solid tumors. It is also developing Vitalzul as a prescription strength oral pharmaceutical, as well as a concentrated intravenous and injectable version for direct administration to a tumor. In addition, the company develops edible dog and cat treats. Petlife Pharmaceuticals, Inc. is based in Los Angeles, California.
Frequently asked questions
What sector does Petlife Pharmaceuticals Inc (PTLF) operate in?
Petlife Pharmaceuticals Inc belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.
What is Petlife Pharmaceuticals Inc (PTLF) current stock price?
As of the latest data, Petlife Pharmaceuticals Inc stock price is $0.00, with a previous close of $0.00.
What is Petlife Pharmaceuticals Inc (PTLF) current market capitalization?
Petlife Pharmaceuticals Inc market cap is approximately 19.68 thousand.
Does Petlife Pharmaceuticals Inc (PTLF) pay dividends?
No. Petlife Pharmaceuticals Inc does not pay a dividend.
What is Petlife Pharmaceuticals Inc (PTLF) beta (volatility) score?
Petlife Pharmaceuticals Inc has a beta of 63.763, indicating very high volatility compared to the market.